Xencor (XNCR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Xencor (XNCR)

XNCR 14.37

+5.0%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (38)	11/6/2014 12:52:36 PM
From: scaram(o)uche	Read Replies (1) of 136

>> second CD123 shot on goal still sitting there, waiting for preclinical << from today's release..... Dr. Dahiyat added, "Based on these data, we have selected XmAb14045, our lead anti-CD123xCD3 bispecific antibody, for IND-enabling studies and cGMP process development and manufacturing at a contract manufacturer. We look forward to bringing this candidate into the clinic within the next 18 months." investors.xencor.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next